Pharmacokinetics and pharmacodynamics of antimicrobials

被引:115
作者
Drusano, G. L. [1 ]
机构
[1] Ordway Res Inst, Albany, NY 12208 USA
关键词
D O I
10.1086/518137
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antibiotics are some of our most commonly used drugs. Until recently, little has been known about how to optimize administration of these agents. Unfortunately, the rate of discovery of new antibiotics has been declining, coincident with the explosion in the number of multidrug-resistant organisms in both the community and hospital environments. This development makes the identification of optimal regimens that will result in good clinical and microbiological outcomes important, but it also makes clear the necessity of identifying regimens that will suppress the emergence of resistant organisms. Given that new agents for multidrug- resistant pathogens will take nearly a decade to become available to physicians, keeping organisms susceptible to drugs that are already available is even more critical. Pharmacodynamics allows identification of the drug exposure measure that is closely associated with the ability to kill organisms and, also, to suppress the emergence of resistant subpopulations of organisms. Use of Monte Carlo simulation allows identification of drug doses in the clinical arena to accomplish these ends. Such approaches should be applied to all old and new antibacterial agents.
引用
收藏
页码:S89 / S95
页数:7
相关论文
共 28 条
[1]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[2]   INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS [J].
CRAIG, WA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) :89-96
[3]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[4]   AN EVALUATION OF OPTIMAL SAMPLING STRATEGY AND ADAPTIVE STUDY DESIGN [J].
DRUSANO, GL ;
FORREST, A ;
SNYDER, MJ ;
REED, MD ;
BLUMER, JL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (02) :232-238
[5]   Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia [J].
Drusano, GL ;
Preston, SL ;
Fowler, C ;
Corrado, M ;
Weisinger, B ;
Kahn, J .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (09) :1590-1597
[6]   OPTIMAL SAMPLING THEORY AND POPULATION MODELING - APPLICATION TO DETERMINATION OF THE INFLUENCE OF THE MICROGRAVITY ENVIRONMENT ON DRUG DISTRIBUTION AND ELIMINATION [J].
DRUSANO, GL .
JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (10) :962-967
[7]   OPTIMAL SAMPLING THEORY - EFFECT OF ERROR IN A NOMINAL PARAMETER VALUE ON BIAS AND PRECISION OF PARAMETER-ESTIMATION [J].
DRUSANO, GL ;
FORREST, A ;
YUEN, G ;
PLAISANCE, K ;
LESLIE, J .
JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (10) :967-974
[8]   A PROSPECTIVE EVALUATION OF OPTIMAL SAMPLING THEORY IN THE DETERMINATION OF THE STEADY-STATE PHARMACOKINETICS OF PIPERACILLIN IN FEBRILE NEUTROPENIC CANCER-PATIENTS [J].
DRUSANO, GL ;
FORREST, A ;
PLAISANCE, KI ;
WADE, JC .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (06) :635-641
[9]   Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint [J].
Drusano, GL ;
Preston, SL ;
Hardalo, C ;
Hare, R ;
Banfield, C ;
Andes, D ;
Vesga, O ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :13-22
[10]   PHARMACODYNAMICS OF A FLUOROQUINOLONE ANTIMICROBIAL AGENT IN A NEUTROPENIC RAT MODEL OF PSEUDOMONAS SEPSIS [J].
DRUSANO, GL ;
JOHNSON, DE ;
ROSEN, M ;
STANDIFORD, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :483-490